SCHEMBL678627

SCHEMBL678627

O=C(O)CCC(=O)c1ccc2[nH]c3ncccc3c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
PARP1 P09874 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CHEK1 O14757 1/20 0.42
CTNNB1 P35222 6/20 0.42
WNT3A P56704 6/20 0.42
NR4A2 P43354 1/20 0.41
FFAR1 O14842 1/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HIF1A Q16665 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675148 0.84 MEN1 (0.44) GSK3AGSK3BCDK5CDK5R1PARP1
SCHEMBL676547 0.84 GSK3B (0.55) GSK3AGSK3BCDK5CDK5R1PARP1
SCHEMBL677968 0.82 MAPT (0.46) GSK3AGSK3BCDK5CDK5R1PARP1
SCHEMBL675443 0.81 MAP2 (0.44) CYP1A2GSK3BPARP1KMT2ACTNNB1
SCHEMBL677456 0.80 ALK (0.47) GSK3AGSK3BCDK5CDK5R1PARP1
SCHEMBL675910 0.80 PARP1 (0.46) CYP1A2GSK3AGSK3BCDK5PARP1
SCHEMBL676505 0.80 RIPK1 (0.50) GSK3AGSK3BCDK5CDK5R1PARP1
SCHEMBL675383 0.80 ERBB2 (0.55) GSK3AGSK3BCDK5CDK5R1PARP1
SCHEMBL674652 0.79 CYP1A2 (0.43) CYP1A2GSK3BPARP1KMT2ACTNNB1
SCHEMBL5436301 0.77 KIF11 (0.56) CYP1A2GSK3BPARP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 CYP1A2 1915/4885GSK3A 131/4885GSK3B 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.